https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:22:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-22T02:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-22T02:22:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-laryngeal-cancer-likelihood-of-approval/ 2025-01-22T02:22:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:22:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:22:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T02:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T02:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mecasermin-rinfabate-chiesi-farmaceutici-bronchopulmonary-dysplasia-likelihood-of-approval/ 2025-01-22T02:22:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T02:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T02:22:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vk-2809-viking-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-22T02:22:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saracatinib-difumarate-astrazeneca-psychosis-likelihood-of-approval/ 2024-06-17T06:41:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T02:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-pulmonary-arterial-hypertension-likelihood-of-approval/ 2025-01-22T02:22:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T02:22:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-follicular-lymphoma-likelihood-of-approval-2/ 2025-01-22T01:58:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-22T01:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-systemic-sclerosis-scleroderma-likelihood-of-approval-2/ 2025-01-22T01:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-chondrosarcoma-likelihood-of-approval/ 2025-01-22T02:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selumetinib-sulfate-astrazeneca-low-grade-glioma-likelihood-of-approval/ 2024-06-17T06:39:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belimumab-gsk-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-22T02:21:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T02:21:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-solid-tumor-likelihood-of-approval/ 2025-01-22T02:21:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixisenatide-sanofi-parkinson-s-disease-likelihood-of-approval/ 2025-01-22T02:21:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zibotentan-astrazeneca-diabetic-nephropathy-likelihood-of-approval/ 2024-07-05T18:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-liposarcoma-likelihood-of-approval/ 2024-06-17T06:35:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2025-01-22T02:21:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alisertib-puma-biotechnology-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-22T02:21:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-myelofibrosis-likelihood-of-approval/ 2025-01-22T02:21:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2025-01-22T02:21:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enobosarm-veru-obesity-likelihood-of-approval/ 2025-01-22T02:21:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sunitinib-malate-pfizer-basaloid-squamous-cell-carcinoma-likelihood-of-approval/ 2024-06-17T06:32:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T02:21:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sunitinib-malate-pfizer-squamous-cell-carcinoma-likelihood-of-approval/ 2024-06-17T06:32:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sunitinib-malate-pfizer-thymoma-thymic-epithelial-tumor-likelihood-of-approval/ 2024-06-17T06:32:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ixazomib-citrate-millennium-pharmaceuticals-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2024-09-09T06:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relugolix-takeda-pharmaceutical-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2025-01-22T02:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:21:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:21:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-myelofibrosis-likelihood-of-approval/ 2025-01-22T02:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-22T02:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-22T02:20:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nilotinib-novartis-acral-lentiginous-melanoma-likelihood-of-approval/ 2024-06-17T06:29:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramosetron-astellas-pharma-fecal-incontinence-likelihood-of-approval/ 2024-06-17T06:29:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T06:18:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T02:20:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T02:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-ovarian-cancer-likelihood-of-approval/ 2025-01-22T02:20:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brivaracetam-ucb-epilepsy-likelihood-of-approval/ 2024-09-09T06:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dapagliflozin-propanediol-astrazeneca-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-22T02:20:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T02:20:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blarcamesine-hydrochloride-anavex-life-sciences-fragile-x-syndrome-likelihood-of-approval/ 2025-01-22T02:20:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T02:20:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/roches-columvi-competes-in-bite-battle-with-positive-results-in-dlbcl/ 2024-06-16T23:50:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-signs-option-agreement-with-ascentage-for-cml-drug/ 2024-06-14T16:39:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pre-diabetes-rates-increase-amidst-a-renaissance-for-type-2-diabetes-research/ 2024-06-14T16:23:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approval-bms-augtyro/ 2024-06-17T06:34:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santa-ana-bio-inflammatory-disease/ 2024-06-14T10:15:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/suven-acquire-sapala-organics/ 2025-01-20T09:43:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-futuregen-collaborate-ibd/ 2024-06-14T08:02:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/uks-new-netflix-style-funding-model-for-antibiotics-goes-live/ 2024-06-13T20:50:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-267-nextpoint-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T18:25:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-luye-pharma-group-post-menopausal-osteoporosis-likelihood-of-approval/ 2024-06-14T02:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/setrusumab-ultragenyx-pharmaceutical-osteogenesis-imperfecta-likelihood-of-approval/ 2024-07-05T05:47:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snipr-001-snipr-biome-escherichia-coli-infections-likelihood-of-approval-2/ 2024-12-25T17:35:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tdm-180935-technoderma-medicines-atopic-dermatitis-atopic-eczema-likelihood-of-approval-2/ 2024-12-25T17:18:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bmb-101-bright-minds-biosciences-dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-likelihood-of-approval-2/ 2024-12-25T17:12:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-and-abpi-announce-new-guidelines-ahead-of-uk-elections/ 2024-06-14T09:45:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/leo-single-dose-autoinjector-secures-fda-approval-for-atopic-dermatitis/ 2024-06-13T15:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/barinthus-bio-slashes-headcount-by-25-and-refocuses-pipeline/ 2024-06-13T15:38:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/flagship-pioneering-profound-obesity/ 2024-06-13T10:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-ochre-bio-partnership/ 2024-06-13T10:05:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alzheon-alzheimers-disease-treatment/ 2024-06-13T08:33:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-three-point-plan-amanda-pritchard/ 2024-06-13T09:16:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-astrazeneca-farxiga/ 2024-06-13T08:27:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/study-finds-most-patients-in-target-nash-registry-meet-revised-masld-criteria/ 2024-06-12T23:01:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/data-sharing-will-be-key-in-repairing-the-uk-clinical-ecosystem/ 2024-06-12T22:32:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/thinking-outside-of-the-box-digitising-pharmacy-dispensing-labels/ 2024-06-12T22:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bankrupt-mithra-cashes-in-on-remaining-assets-for-188-2m/ 2024-06-12T22:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/south-korea-and-australia-on-the-rise-as-clinical-research-hubs/ 2024-06-14T19:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/anti-obesity-drugs-will-be-2024s-defining-trend/ 2024-06-12T12:32:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/siegfried-cdmo-acquisition-us/ 2024-06-12T10:23:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cyrus-biotechnology-levitate-bio/ 2024-06-12T10:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/syntis-bio-metabolic-diseases/ 2024-06-12T08:19:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-kgaa-life-science-facility-germany/ 2024-06-12T08:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-champions-early-kidney-disease-diagnosis-with-modelling-data/ 2024-06-12T12:02:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tacalyx-extends-seed-funding-round-to-raise-over-14m/ 2024-06-12T12:03:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-clinical-trial-sector-must-address-subpar-timelines-say-experts/ 2024-06-12T12:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-backed-bright-peak-secures-90m-to-advance-immunoconjugate-programme/ 2024-06-12T12:08:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amphastar-pharmaceuticals-gets-grant-for-medication-container-assembly-with-cap-and-hold-down-members/ 2024-06-11T13:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/piramal-enterprises-gets-grant-for-pharmaceutical-kit-for-cancer-treatment-with-cdk-and-antioxidant/ 2024-06-12T12:10:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biomarin-pharmaceutical-gets-grant-for-treatment-of-adolescent-pku-patients-using-avpal-variant-2/ 2024-06-11T13:20:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/silence-therapeutics-gets-grant-for-compound-for-rna-interference-therapy-in-treating-liver-disease/ 2024-06-11T13:20:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syros-pharmaceuticals-gets-grant-for-cdk7-inhibitors-for-treating-cancer-and-other-diseases-2/ 2024-06-11T13:19:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/united-laboratories-international-gets-grant-for-method-for-removing-contaminant-material-from-oil-and-gas-equipment/ 2024-06-11T13:19:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eurofins-scientific-gets-grant-for-detection-of-dna-from-specific-cells-for-medical-conditions/ 2024-06-11T13:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kineta-gets-grant-for-compounds-for-treating-proteostasis-dysfunction/ 2024-06-11T13:19:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purdue-pharma-gets-grant-for-tamper-resistant-opioid-analgesic-extended-release-dosage-form/ 2024-06-11T13:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ultragenyx-pharmaceutical-gets-grant-for-method-of-protecting-aav-viral-particles-during-heat-inactivation/ 2024-06-11T13:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teladoc-health-gets-grant-for-contextual-video-search-method-for-telepresence-device/ 2024-06-11T13:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esperion-therapeutics-gets-grant-for-patent-granted-for-method-of-lowering-ldl-c-using-pharmaceutical-material/ 2024-06-11T13:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allakos-gets-grant-for-anti-siglec-7-antibody-for-cancer-treatment/ 2024-06-11T13:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arvinas-gets-grant-for-bifunctional-compounds-degrading-and-inhibiting-androgen-receptor/ 2024-06-11T13:17:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptc-therapeutics-gets-grant-for-composition-of-polymorphic-forms-of-r-2-hydroxy-2-methyl-4-2-4-5-trimethyl-3-6-dioxocyclohexa-1-4-dienyl-butanamide/ 2024-06-11T13:17:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chong-kun-dang-pharmaceutical-gets-grant-for-patent-granted-for-hdac6-inhibitory-compounds-for-treating-diseases/ 2024-06-11T13:16:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csl-gets-grant-for-formulation-for-reconstituted-high-density-lipoprotein-with-lyophilization-stabilizer/ 2024-06-11T13:16:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crinetics-pharmaceuticals-gets-grant-for-patent-granted-for-oral-method-to-suppress-hormones/ 2024-06-11T13:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/twist-bioscience-gets-grant-for-covalently-linked-polymerase-and-phosphorylated-nucleoside-for-polynucleotide-synthesis/ 2024-06-11T13:16:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sun-pharmaceutical-industries-gets-grant-for-topical-ophthalmic-formulation-for-treating-inflammatory-ocular-disease/ 2024-06-11T13:15:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yield10-bioscience-gets-grant-for-transgenic-plants-with-enhanced-seed-yield-and-oil-content/ 2024-06-11T13:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-macrocyclic-compounds-inhibiting-coronavirus-replication/ 2024-06-11T13:15:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zealand-pharma-gets-grant-for-compstatin-analogues-with-improved-binding-and-complement-inhibiting-activity/ 2024-06-11T13:15:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sorrento-therapeutics-gets-grant-for-implantable-device-for-delivering-bioactive-agents-without-immune-response-2/ 2024-06-11T13:14:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senju-pharmaceutical-gets-grant-for-treatment-of-retinal-and-nerve-diseases-using-laminin-511/ 2024-06-11T13:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precigen-gets-grant-for-method-for-integrating-genes-into-pbmc-genome/ 2024-06-11T13:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celltrion-gets-grant-for-stable-liquid-pharmaceutical-formulation-containing-infliximab/ 2024-06-11T13:13:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arbutus-biopharma-gets-grant-for-method-of-treating-infusion-reaction-with-lipid-formulated-therapeutic-agent-2/ 2024-06-11T13:13:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orexo-gets-grant-for-pharmaceutical-composition-for-nasal-delivery-of-epinephrine/ 2024-06-11T13:13:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/karyopharm-therapeutics-gets-grant-for-treatment-of-disorders-associated-with-crm1-activity/ 2024-06-11T13:13:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogaia-gets-grant-for-melatonin-producing-lactobacillus-bacterial-strains/ 2024-06-11T13:12:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zhejiang-huahai-pharmaceutical-gets-grant-for-method-for-preparing-pregabalin-using-biological-enzymes-and-isomerase/ 2024-06-11T13:12:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iovance-biotherapeutics-gets-grant-for-method-for-treating-melanoma-with-re-stimulated-til-populations/ 2024-06-11T13:12:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/protagonist-therapeutics-gets-grant-for-peptide-inhibitors-of-il-23-receptor-for-autoimmune-inflammation/ 2024-06-11T13:12:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shilpa-medicare-gets-grant-for-patent-granted-for-crystalline-form-of-bortezomib/ 2024-06-11T13:11:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radius-health-gets-grant-for-patent-granted-for-treating-prader-willi-syndrome-with-cannabidiol-formulation-2/ 2024-06-11T13:11:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teva-pharmaceutical-industries-gets-grant-for-inhaler-with-multiple-outlets-and-deagglomerator-for-powder-medication/ 2024-06-11T13:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eli-lilly-and-co-gets-grant-for-treatment-of-ret-associated-cancers-with-compound-of-formula-i/ 2024-06-11T13:11:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voyager-therapeutics-gets-grant-for-sirna-molecules-for-treating-huntington-s-disease/ 2024-06-11T13:10:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elanco-animal-health-gets-grant-for-polypeptides-for-treating-il13-and-il4-induced-conditions-in-animals/ 2024-06-11T13:10:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-gets-grant-for-treatment-of-mycobacterial-infections-including-tuberculosis/ 2024-06-11T13:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avidity-biosciences-gets-grant-for-polynucleic-acid-conjugate-for-treating-fshd-through-rna-interference-2/ 2024-06-11T13:09:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldeyra-therapeutics-gets-grant-for-treatment-of-retinitis-pigmentosa-with-methotrexate-eye-injections-2/ 2024-06-11T13:09:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pmv-pharmaceuticals-gets-grant-for-deuterium-substituted-indoles-for-binding-mutant-p53-protein/ 2024-06-11T13:09:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revolution-medicines-gets-grant-for-inhibiting-ras-proteins-for-cancer-treatment-2/ 2024-06-11T13:09:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/recursion-pharmaceuticals-gets-grant-for-pharmaceutical-compounds-for-treating-diseases-2/ 2024-06-11T13:08:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ose-immunotherapeutics-gets-grant-for-humanized-monoclonal-antibodies-for-inhibiting-inflammation-in-il-7-pathway/ 2024-06-11T13:08:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pieris-pharmaceuticals-gets-grant-for-fusion-polypeptide-binding-cd137-and-gpc3-for-cancer-treatment-2/ 2024-06-11T13:08:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denali-therapeutics-gets-grant-for-treating-diseases-mediated-by-eukaryotic-initiation-factor-2b/ 2024-06-11T13:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ovid-therapeutics-gets-grant-for-treatment-of-status-epilepticus-with-ganaxolone-continuous-intravenous-infusion-2/ 2024-06-11T13:07:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/adcytherix-launch-adc-development/ 2024-06-11T10:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-priority-review-tagrisso/ 2024-06-11T10:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kyowa-kirin-biologics-facility/ 2024-06-11T08:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-approval-iqirvo-pbc/ 2024-06-11T08:17:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-253-kymera-therapeutics-net-present-value/ 2024-07-02T02:06:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-442970-sanofi-net-present-value/ 2024-12-13T02:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-net-present-value/ 2024-09-08T18:17:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-777-apogee-therapeutics-net-present-value/ 2024-12-13T02:52:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-net-present-value/ 2024-07-02T02:06:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lunsekimig-sanofi-net-present-value/ 2024-07-02T02:06:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eo-3021-elevation-oncology-net-present-value/ 2024-07-02T02:06:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrdn-003-viridian-therapeutics-net-present-value/ 2024-06-11T02:29:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navenibart-astria-therapeutics-net-present-value/ 2024-07-02T02:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tacrolimus-tff-pharmaceuticals-net-present-value/ 2024-06-11T02:27:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-129-merus-net-present-value/ 2024-07-02T02:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/istisociclib-kronos-bio-net-present-value/ 2024-06-11T02:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frespaciguat-merck-net-present-value/ 2024-12-13T02:51:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monlunabant-novo-nordisk-net-present-value/ 2024-07-02T02:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zodasiran-arrowhead-pharmaceuticals-net-present-value/ 2024-07-02T02:06:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opevesostat-merck-net-present-value/ 2024-12-13T02:51:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar444656-sanofi-net-present-value/ 2024-06-11T02:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065845-neurocrine-biosciences-net-present-value/ 2024-06-11T02:23:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naporafenibum-erasca-net-present-value/ 2024-06-11T02:23:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inbrx-101-sanofi-net-present-value/ 2024-12-13T02:51:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enobosarm-veru-net-present-value/ 2024-06-11T02:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-committee-unanimously-backs-lillys-donanemab-bid-for-alzheimers/ 2024-06-10T21:31:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-and-zealand-intensify-glp1-ra-mash-race/ 2024-06-10T19:19:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/four-key-trends-in-the-clinical-trial-supply-chain/ 2024-06-12T09:19:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-extends-marengo-partnership-with-1bn-t-cell-research-deal/ 2024-06-10T15:59:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/monthly-iv-version-of-leqembi-set-for-fda-review-next-year/ 2024-06-10T15:49:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shanghai-junshi-bioscience-gets-grant-for-isotope-enriched-compounds-for-improving-drug-delivery-and-efficacy/ 2024-06-10T12:39:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapt-therapeutics-gets-grant-for-inhibiting-hematopoietic-progenitor-kinase-1-using-pyrazole-pyrimidine-compounds-2/ 2024-06-10T12:38:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abcellera-biologics-gets-grant-for-transgenic-mouse-with-long-hcdr3-immunoglobulin-library-production/ 2024-06-10T12:38:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vir-biotechnology-gets-grant-for-monoclonal-antibody-for-treating-staphylococcus-aureus-infection/ 2024-06-10T12:38:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cue-biopharma-gets-grant-for-method-of-treating-cancer-with-immune-checkpoint-inhibitor-and-protein/ 2024-06-10T12:38:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenaya-therapeutics-gets-grant-for-compound-for-treating-diseases-by-inhibiting-hdac6-activity-2/ 2024-06-10T12:37:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sword-health-gets-grant-for-motion-tracking-system-controlled-by-sound-and-electromagnetic-waves/ 2024-06-10T12:37:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aligos-therapeutics-gets-grant-for-patent-granted-for-compounds-treating-diseases-and-conditions/ 2024-06-10T12:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ikena-oncology-gets-grant-for-cancer-treatment-method-using-compounds-of-formula-i-2/ 2024-06-10T12:37:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kodiak-sciences-gets-grant-for-method-of-treating-eye-disorder-with-anti-vegf-antibody-conjugate/ 2024-06-10T12:36:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytokinetics-gets-grant-for-pharmaceutical-composition-and-methods-of-using-compound-of-formula-i/ 2024-06-10T12:36:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kobayashi-pharmaceutical-gets-grant-for-chemical-body-warmer-generating-heat-effectively-in-low-temperatures/ 2024-06-10T12:36:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/northwest-biotherapeutics-gets-grant-for-cell-culture-system-with-symmetrical-fluid-flow-channels/ 2024-06-10T12:36:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nurix-therapeutics-gets-grant-for-patent-granted-for-cbl-b-inhibitors-for-immune-system-modulation/ 2024-06-10T12:35:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/genmab-gets-grant-for-multispecific-antibody-binding-to-human-cd40-and-cd137/ 2024-06-10T12:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medicinova-gets-grant-for-treatment-of-progressive-neurodegenerative-diseases-with-ibudilast/ 2024-06-10T12:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zhejiang-hisun-pharmaceutical-gets-grant-for-irak4-inhibitors-represented-by-indazole-derivatives-of-formula-i-2/ 2024-06-10T12:35:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epivax-gets-grant-for-method-of-inducing-regulatory-t-cells-to-suppress-immune-response/ 2024-06-10T12:34:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trevena-gets-grant-for-opioid-receptor-ligands-for-pain-treatment/ 2024-06-10T12:34:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innate-pharma-gets-grant-for-treatment-of-ctcl-using-kir3dl2-targeting-antibodies/ 2024-06-10T12:34:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lixte-biotechnology-gets-grant-for-treatment-of-glioblastoma-with-pp2a-inhibitor-and-monosodium-glutamate/ 2024-06-10T12:33:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/towa-pharmaceutical-gets-grant-for-resin-molding-apparatus-with-reduced-thickness-variation/ 2024-06-10T12:33:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arrowhead-pharmaceuticals-gets-grant-for-dsrna-for-inhibiting-rrm2-gene-expression-2/ 2024-06-10T12:33:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/redhill-biopharma-gets-grant-for-combination-capsule-for-h-pylori-treatment/ 2024-06-10T12:33:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/galecto-gets-grant-for-treatment-of-disorder-related-to-galectin-3-binding-in-mammals/ 2024-06-10T12:32:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/actinium-pharmaceuticals-gets-grant-for-bifunctional-chelators-for-radiolabeled-cancer-antigen-targeting-agents/ 2024-06-10T12:32:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inhibrx-gets-grant-for-fusion-protein-with-aat-and-hsa-polypeptides/ 2024-06-10T12:32:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/editas-medicine-gets-grant-for-genome-editing-system-for-altering-target-nucleic-acid/ 2024-06-10T12:32:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acadia-pharmaceuticals-gets-grant-for-treating-prader-willi-syndrome-with-pde4-inhibitor/ 2024-06-10T12:31:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fate-therapeutics-gets-grant-for-cell-therapy-for-treating-human-subjects-with-modulated-immune-cells/ 2024-06-10T12:31:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shenzhen-hepalink-pharmaceutical-group-gets-grant-for-pancreatin-preparation-with-reduced-viral-infectivity/ 2024-06-10T12:31:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/molecular-templates-gets-grant-for-pd-l1-binding-molecule-for-cancer-treatment/ 2024-06-10T12:31:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/proqr-therapeutics-gets-grant-for-oligonucleotide-for-reducing-aberrant-splice-site-selection-in-cep290-gene-2/ 2024-06-10T12:30:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crispr-therapeutics-gets-grant-for-masked-car-construct-targeting-ptk7-for-t-cell-therapy/ 2024-06-10T12:30:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agios-pharmaceuticals-gets-grant-for-activating-compounds-for-pyruvate-kinase-r/ 2024-06-10T12:30:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intellia-therapeutics-gets-grant-for-treating-amyloidosis-associated-with-ttr-gene-using-compositions/ 2024-06-10T12:30:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/unity-biotechnology-gets-grant-for-treating-retinal-vasculopathies-with-compound-meglumine/ 2024-06-10T12:29:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eyenovia-gets-grant-for-device-for-delivering-fluid-to-eye-using-vibrating-element/ 2024-06-10T12:29:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/beyondspring-gets-grant-for-treating-cancer-expressing-mutant-ras-protein-with-plinabulin-2/ 2024-06-10T12:29:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innocare-pharma-gets-grant-for-patent-granted-for-crystalline-form-of-specific-pharmaceutical-compound/ 2024-06-10T12:29:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/springworks-therapeutics-gets-grant-for-treatment-of-desmoid-tumor-with-nirogacestat/ 2024-06-10T12:28:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arcus-biosciences-gets-grant-for-compounds-modulating-amp-to-adenosine-for-treating-diseases/ 2024-06-10T12:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alector-gets-grant-for-anti-siglec-5-antibody-for-treating-alzheimer-s-disease-and-cancer/ 2024-06-10T12:28:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/children-s-medical-center-gets-grant-for-treatment-of-neurological-diseases-by-reconstituting-brain-myeloid-cells/ 2024-06-10T12:28:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/community-health-systems-gets-grant-for-portable-sleep-diagnostic-system-for-remote-sleep-apnea-testing-2/ 2024-06-10T12:27:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zhejiang-medicine-gets-grant-for-method-for-extracting-and-isolating-lutein-crystal-from-vegetable-oil-2/ 2024-06-10T12:27:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/boston-children-s-hospital-gets-grant-for-phenothiazine-compound-for-treating-ribosomal-disorders/ 2024-06-10T12:27:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ayala-pharmaceuticals-gets-grant-for-recombinant-fusion-polypeptides-for-cancer-immunotherapy-2/ 2024-06-10T12:27:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emergent-biosolutions-gets-grant-for-treatment-for-toxoplasma-gondii-infection-using-chimeric-polypeptides/ 2024-06-10T12:26:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-biotechnology-gets-grant-for-vaccine-composition-with-cationic-lipid-for-immune-response-enhancement-2/ 2024-06-10T12:26:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/almirall-klisyri-actinic-keratosis/ 2024-06-10T10:57:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-updated-covid-19-vaccine/ 2024-06-10T10:07:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alecensa-ec-approval-roche/ 2024-06-10T08:15:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-rsv-vaccine-fda-approval/ 2024-06-10T08:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco24-another-win-for-opdivo-yervoy-in-first-line-hcc-despite-uncertainties/ 2024-06-07T18:26:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chromadex-wins-orphan-designation-for-rare-ataxia-drug/ 2024-06-07T17:28:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-admonishes-jiangsu-hengrui-manufacturing-site-following-inspection/ 2024-06-07T20:25:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/orano-med-unveils-radiopharma-manufacturing-plant-in-indianapolis/ 2024-06-07T16:34:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-releases-report-adcom-donanemab-trial/ 2024-06-07T19:20:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/agomab-wins-fda-orphan-drug-status-for-idiopathic-pulmonary-fibrosis-asset/ 2024-06-07T15:54:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ukraine-market-access-review-two-years-war/ 2024-07-22T12:34:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avadel-pharmaceuticals-gets-grant-for-patent-granted-for-modified-release-formulation-of-gamma-hydroxybutyrate-2/ 2024-06-07T11:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zydus-lifesciences-gets-grant-for-oral-suspension-of-mycophenolate-mofetil/ 2024-06-07T11:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allscripts-healthcare-solutions-gets-grant-for-optimizing-patient-overview-in-user-interface-for-medical-processing-device/ 2024-06-07T11:35:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amneal-pharmaceuticals-gets-grant-for-patent-granted-for-floating-gastroretentive-composition-with-sustained-release/ 2024-06-07T11:34:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cspc-pharmaceutical-group-gets-grant-for-pharmaceutical-formulation-for-treating-inflammatory-or-neurodegenerative-diseases-2/ 2024-06-07T11:34:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/heidelberg-pharma-gets-grant-for-amanitin-derivative-conjugates-for-treating-cancer/ 2024-06-07T11:34:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syndax-pharmaceuticals-gets-grant-for-inhibitors-of-menin-mll-interaction-for-cancer-treatment-2/ 2024-06-07T11:33:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botanix-pharmaceuticals-gets-grant-for-topical-treatment-for-dermatitis-with-cannabidiol-in-specific-composition-2/ 2024-06-07T11:33:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/curevac-gets-grant-for-pharmaceutical-composition-for-rsv-vaccine-with-modified-fusion-protein/ 2024-06-07T11:33:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envision-healthcare-gets-grant-for-medical-imaging-distribution-system-with-prioritized-radiologist-queues-2/ 2024-06-07T11:33:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/athersys-gets-grant-for-method-for-treating-cutaneous-burn-wounds-using-non-embryonic-cells/ 2024-06-07T11:32:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mayo-clinic-gets-grant-for-brain-electrode-device-with-contact-points-sub-circuits-and-multiplexer/ 2024-06-07T11:32:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/halozyme-therapeutics-gets-grant-for-modified-ph20-hyaluronidase-polypeptides-with-increased-stability-activity/ 2024-06-07T11:32:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novavax-gets-grant-for-vaccine-for-treating-or-preventing-c-difficile-bacterial-infection/ 2024-06-07T11:32:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncopeptides-gets-grant-for-lyophilized-pharmaceutical-preparation-for-cancer-therapy-2/ 2024-06-07T11:31:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/harrow-health-gets-grant-for-preservative-free-ophthalmic-composition-for-ocular-diseases/ 2024-06-07T11:31:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/morphosys-gets-grant-for-generating-variants-of-anti-cd38-antibody-using-specific-sequences/ 2024-06-07T11:31:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memorial-sloan-kettering-cancer-center-gets-grant-for-method-for-differentiating-pluripotent-stem-cells-into-dopamine-neurons/ 2024-06-07T11:31:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kala-pharmaceuticals-gets-grant-for-ocular-treatment-method-using-msc-derived-fibronectin-composition-2/ 2024-06-07T11:30:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alkermes-gets-grant-for-long-term-stable-pharmaceutical-composition-with-hydrolytically-labile-antipsychotic-agent/ 2024-06-07T11:30:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/catalent-gets-grant-for-antibodies-binding-to-mucin-1-for-therapeutic-and-diagnostic-use/ 2024-06-07T11:30:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/otsuka-gets-grant-for-oral-dosage-form-providing-equivalent-decitabine-levels-to-iv-infusion/ 2024-06-07T11:30:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirum-pharmaceuticals-gets-grant-for-treatment-of-cholestatic-pruritus-in-alagille-syndrome-with-maralixibat-2/ 2024-06-07T11:29:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sanbio-gets-grant-for-method-for-inducing-polarization-in-stem-cells-for-therapy/ 2024-06-07T11:29:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/theravance-biopharma-gets-grant-for-prodrugs-with-neprilysin-inhibition-activity-2/ 2024-06-07T11:29:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/23andme-gets-grant-for-predicting-familial-relationships-based-on-shared-dna-segments/ 2024-06-07T11:28:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avantor-gets-grant-for-patent-granted-for-composition-with-specific-fluorosilicone-formulation/ 2024-06-07T11:28:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ginkgo-bioworks-gets-grant-for-gene-therapy-composition-for-treating-npc1-using-aav-vectors-2/ 2024-06-07T11:28:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyorin-gets-grant-for-antiviral-compound-for-picornavirus-specifically-rhinovirus/ 2024-06-07T11:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hanall-biopharma-gets-grant-for-anti-fcrn-antibody-with-improved-stability-for-autoimmune-disease-treatment/ 2024-06-07T11:27:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melinta-therapeutics-gets-grant-for-intravenous-formulation-with-minocycline-and-magnesium-for-reduced-hemolysis/ 2024-06-07T11:27:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atara-biotherapeutics-gets-grant-for-treatment-of-solid-malignant-tumors-using-antigen-specific-t-cells/ 2024-06-07T11:27:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avacta-group-gets-grant-for-polypeptide-with-n32g-mutation-and-heterologous-peptides/ 2024-06-07T11:27:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cipla-gets-grant-for-long-term-storage-stable-pharmaceutical-liquid-formulation-with-pemetrexed/ 2024-06-07T11:26:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caribou-biosciences-gets-grant-for-monoclonal-antibody-for-ror1-cancer-treatment/ 2024-06-07T11:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cardiff-oncology-gets-grant-for-combination-treatment-for-lung-or-gastric-cancer/ 2024-06-07T11:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/henry-ford-health-system-gets-grant-for-treatment-of-cardiovascular-disorders-with-microrna-126-containing-exosomes/ 2024-06-07T11:26:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adc-therapeutics-gets-grant-for-treatment-of-cd19-cancer-or-autoimmune-disease-with-cd19-adcs/ 2024-06-07T11:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lupin-gets-grant-for-treatment-of-cancer-by-inhibiting-prmt5-enzyme/ 2024-06-07T11:25:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/infinity-pharmaceuticals-gets-grant-for-treatment-of-hematological-cancer-using-specific-pharmaceutical-compositions/ 2024-06-07T11:25:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kura-oncology-gets-grant-for-treating-leukemia-with-menin-inhibitors/ 2024-06-07T11:25:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stealth-biotherapeutics-gets-grant-for-treating-age-related-macular-degeneration-with-specific-peptide/ 2024-06-07T11:24:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxcyte-gets-grant-for-immunogenic-compositions-containing-non-natural-amino-acids-for-vaccines/ 2024-06-07T11:24:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aptevo-therapeutics-gets-grant-for-recombinant-polypeptide-for-cancer-treatment/ 2024-06-07T11:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/homology-medicines-gets-grant-for-treatment-of-phenylketonuria-using-recombinant-adeno-associated-virus/ 2024-06-07T11:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amylyx-pharmaceuticals-gets-grant-for-treatment-of-als-symptoms-with-taurursodiol-and-sodium-phenylbutyrate/ 2024-06-07T11:23:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/i-mab-gets-grant-for-anti-gm-csf-antibodies-for-treating-inflammatory-diseases/ 2024-06-07T11:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioxcel-therapeutics-gets-grant-for-method-of-treating-agitation-in-alzheimer-s-disease-patients/ 2024-06-07T11:23:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prelude-therapeutics-gets-grant-for-pharmaceutical-compound-of-formula-i/ 2024-06-07T11:23:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/organon-co-gets-grant-for-uterine-hemorrhage-controlling-system-and-method/ 2024-06-07T11:22:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cycle-offers-to-acquire-vanda/ 2024-06-28T10:35:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/itm-investment-radiopharmaceutical-pipeline/ 2024-06-07T10:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-geron-rytelo/ 2024-06-07T08:08:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-acquires-elsie-oligonucleotide/ 2024-06-07T08:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-recommends-updated-covid-19-vaccines-targeting-jn-1/ 2024-06-06T16:48:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/podcast-3-doing-digital-deals-in-life-sciences-defining-valuing-the-asset/ 2025-03-28T16:18:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-roche-and-others-named-in-italian-anti-competition-probe/ 2024-06-06T16:39:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/tiny-pills-shockwaves-immunology/ 2024-06-07T20:32:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/revolutionising-cystic-fibrosis-treatment-cf/ 2024-06-06T15:55:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-and-myrtelle-among-those-picked-for-fda-rare-disease-programme/ 2024-06-06T14:39:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/osteal-raises-50m-to-bring-joint-infection-drug-device-combo-to-market/ 2024-06-06T10:37:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/european-pharma-regulation-changes-signal-tumult-and-transformation/ 2024-06-06T10:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dcgi-orchid-pharma-enmetazobactam/ 2024-06-06T10:17:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-distribution-centre-germany/ 2024-06-06T10:09:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/data-needed-to-forge-the-link-between-ai-and-mrna/ 2024-06-06T10:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/i-mab-bms-gastric-cancers/ 2024-06-06T08:28:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/arrivent-alphamab-adcs-cancer/ 2024-06-06T08:21:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bluejay-touts-positive-data-for-chronic-hepatitis-d-treatment/ 2024-06-05T17:20:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/scientists-push-for-greener-drugs-in-published-study/ 2024-06-06T08:25:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-hearing-set-to-discuss-advisory-committee-members-conflicts-and-more/ 2024-06-05T22:42:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-sourcing-and-afrigen-biologics-partner-on-biomanufacturing-platform/ 2024-06-05T11:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-to-streamline-your-pharma-mass-production-by-leveraging-the-korber-ecosystem/ 2024-06-06T14:57:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/be-bio-fda-orphan-drug-status/ 2024-06-05T10:40:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mdma-therapy-wait-goes-on-as-fda-panel-rejects-lykos-ptsd-treatment/ 2024-06-05T10:32:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-rinvoq-paediatric-arthritis/ 2024-06-05T10:26:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnson-approvals-hiv-1/ 2024-06-05T08:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-completes-fusion-acquisition/ 2024-06-05T08:07:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/climate-change-aggravate-multiple-sclerosis/ 2024-06-04T16:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-sanofis-sarclisa-looks-to-gain-an-edge-in-multiple-myeloma/ 2024-06-05T13:17:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco-2024-modernas-mrna-4157-is-poised-to-transform-melanoma-field/ 2024-06-05T15:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/plarmaceutical-waste-closure-systems/ 2025-11-05T11:39:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/biosecure-act-could-impact-us-biopharma-drugs/ 2024-06-04T15:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-alligator-shares-positive-data-for-pancreatic-cancer-drug/ 2024-06-04T14:18:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-shares-fall-9-in-wake-of-zantac-court-ruling/ 2024-06-04T11:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-fast-tracks-quince-therapeutics-rare-ataxia-drug-erydex/ 2024-06-04T10:55:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sun-pharma-philogen-melanoma-therapy/ 2024-06-04T10:13:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aurigene-biologics-facility-hyderabad/ 2024-06-07T04:05:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nih-ai-tool-immunotherapy-outcomes/ 2024-06-04T08:22:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-chmp-astrazeneca-tagrisso/ 2024-06-04T08:08:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco24-can-ambrxs-novel-adc-break-into-the-metastatic-breast-cancer-market/ 2024-06-04T03:19:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-24-american-cancer-society-and-asco-combine-cancer-resource-websites/ 2024-06-05T07:53:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco-2024-tagrisso-approaches-standard-of-care-status-for-nsclc/ 2024-06-07T18:45:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-strikes-deal-with-quralis-for-preclinical-als-candidate/ 2024-06-03T15:47:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-global-brands-are-perceived-by-top-business-leaders/ 2024-06-04T10:02:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/grit-quangang-cell-therapy/ 2024-12-18T10:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-approves-backing-for-first-acanthamoeba-keratitis-treatment/ 2024-06-03T10:49:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-mirum-livmarli-pfic/ 2024-06-03T10:35:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/inline-real-time-pat-tool-is-a-game-changer-for-pharma-granulation-sector/ 2024-06-20T15:31:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cstone-sugemalimab-nsclc/ 2024-06-03T08:27:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-moderna-rsv-mresvia/ 2024-06-03T08:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco24-enhertu-aims-to-replace-herceptin-in-first-line-metastatic-breast-cancer/ 2024-06-03T00:42:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco24-akesos-bispecific-ivonescimab-faces-a-rocky-road-ahead-in-nsclc/ 2024-06-10T19:24:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/amyotrophic-lateral-sclerosis-kols/ 2024-05-31T16:11:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-novartis-scemblix-outperforms-standard-of-care-in-cml/ 2024-06-25T11:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/compound-medication/ 2025-11-05T11:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-ten-late-breaking-data-to-look-for-at-asco-2024/ 2024-05-31T15:40:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dupixent-gets-closer-to-eu-approval-as-the-fda-delays-its-decision-on-copd/ 2024-05-31T15:01:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-endorses-abbvies-skyrizi-for-ulcerative-colitis/ 2024-06-05T12:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/manufacturing-inspections-down-china/ 2024-05-31T14:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/swiss-biotech-ecosystem-recuperates-from-global-financial-instability/ 2025-03-12T19:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/midland-launches-spinal-injury/ 2024-05-31T10:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-bluerock-parkinsons-therapy/ 2024-05-31T10:19:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-breyanzi-fda-approval/ 2024-05-31T08:25:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-biogen-qalsody/ 2024-05-31T08:18:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-completes-the-1-7bn-acquisition-of-inhibrx/ 2024-05-30T19:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/agios-sells-vorasidenib-us-royalties-for-905m/ 2024-05-30T18:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-urged-to-improve-access-to-hiv-drug-by-public-figures-and-celebrities/ 2024-05-30T18:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ikena-staff-and-pipeline-cuts-in-a-bid-to-maximise-value/ 2024-05-30T16:14:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-cell-and-gene-therapy-are-evolving/ 2024-05-30T15:59:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/biosecure-grandfather-amendment/ 2024-05-30T15:16:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/aifa-horizon-scanning-2024-influx-atmps/ 2024-05-30T14:29:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-rocket-pharmaceuticals-rp-a601/ 2024-05-30T10:24:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-teva-austedo-xr/ 2024-05-30T10:18:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/untapped-opportunities-fulfilling-the-promise-of-decentralized-clinical-trials/ 2025-02-18T14:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biontech-cepi-africa-vaccine/ 2024-05-30T08:15:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-to-acquire-eyebio/ 2024-05-30T19:40:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/study-touts-targeted-chemotherapy-delivery-method-using-chicken-feather-protein/ 2024-05-29T16:48:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roches-pi3k-inhibitor-wins-fda-priority-review-for-breast-cancer/ 2024-05-29T16:07:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/arvo-conference-vabysmo-data/ 2024-05-29T15:56:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/peptide-manufacturers/ 2024-07-10T09:04:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-secures-another-ec-approval-for-opdivo-combination/ 2024-05-29T13:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/verona-us-launch-ensifentrine-copd/ 2024-05-29T12:45:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-stakes-80m-on-prothenas-neurodegenerative-candidate/ 2024-05-29T12:37:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/turn-bio-hanall-age-related-therapies/ 2024-05-29T09:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-cartography-cancer-therapies/ 2024-05-29T09:50:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-sterility-testing-solution/ 2024-05-29T08:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-amgen-bkemv/ 2024-05-29T08:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vasomune-wins-fda-fast-track-designation-for-lung-condition-treatment/ 2024-05-28T20:39:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/self-amplifying-rna-and-vaccine-innovation-getting-from-concept-to-clinic/ 2024-05-30T09:20:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/biotech-increase-q1-venture-funding/ 2024-06-04T15:55:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-expands-atopic-dermatitis-scope-with-1-25bn-numab-antibody-purchase/ 2024-05-28T16:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-logistics-service-providers-add-value-for-pharma-companies/ 2024-05-29T10:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-jjs-early-radioligand-prostate-cancer-trial-reports-four-patient-deaths/ 2024-05-28T15:43:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-rakutens-photoimmunotherapy-and-keytruda-combo-shows-efficacy-in-hnscc/ 2024-06-25T11:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asahi-kasei-to-acquire-calliditas/ 2024-05-28T10:43:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/helsinn-angelini-distribution-deal/ 2024-05-28T10:26:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/qut-team-parkinsons-treatment/ 2024-05-28T08:24:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-sanofi-sarclisa-sbla/ 2024-05-28T08:11:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/south-korea-eisai-biogen-leqembi/ 2024-05-27T10:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dimerix-taiba-dmx-200-deal/ 2024-05-27T10:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dr-reddys-novartis-agreement/ 2024-05-29T04:49:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-investment-api-manufacturing/ 2024-05-27T08:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-medilinks-nsclc-and-breast-cancer-adc-shows-early-safety-success/ 2024-05-24T18:19:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-msds-adc-shows-efficacy-in-lung-and-breast-tumours/ 2024-10-30T10:09:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-merus-touts-positive-phase-ii-data-for-head-and-neck-cancer-antibody/ 2024-05-24T15:43:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2024-verastems-combo-therapy-for-pancreatic-cancer-hits-early-trial-success/ 2024-05-24T13:51:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-review-novo-nordisk/ 2024-05-24T10:38:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/grey-wolf-50m-boost/ 2024-05-24T10:34:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/cystic-fibrosis-global-clinical-trials-landscape-and-treatments/ 2024-06-03T08:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-celltrion-omlyclo/ 2024-05-24T08:10:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biocon-handok-liraglutide-commercialisation/ 2024-05-24T08:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-lulas-progress-plan-for-brazil-a-year-on/ 2024-05-23T16:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-outlines-up-to-33-6m-for-cancer-asset-from-ose-therapeutics/ 2024-05-23T15:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/otsuka-cuts-development-for-avp-786-following-phase-iii-flop/ 2024-05-23T15:57:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-starts-1-5bn-cost-cutting-initiative-amidst-declining-covid-19-revenues/ 2024-05-23T15:13:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/overcoming-the-barriers-to-diverse-and-inclusive-patient-recruitment/ 2024-05-23T14:45:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/patients-and-caregivers-driving-innovation-in-drug-development/ 2024-05-23T14:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-nona-monoclonal-antibody/ 2024-05-23T10:08:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-sandoz-biosimilars/ 2024-05-23T10:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-to-acquire-hi-bio/ 2024-05-23T08:25:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-milliporesigma-mirus-bio/ 2024-12-18T10:49:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/pharma-clean-room/ 2024-07-09T11:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evotec-shuts-down-gene-therapy-business-in-light-of-q1-2024-loss/ 2024-05-22T15:39:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-makes-another-obesity-play-funnelling-80m-into-sixpeaks-bio/ 2024-05-22T14:48:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-recommends-rhythms-imcivree-for-rare-genetic-obesity-disorder/ 2024-05-22T14:29:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/nitrosamines-parenteral-packaging-evolving-el-challenges/ 2024-05-22T14:21:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-to-take-advantage-of-the-connected-health-opportunity-in-your-next-drug-launch/ 2024-10-14T14:42:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genmab-acquires-profoundbio/ 2024-05-22T10:35:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alvotech-dr-reddys-avt03/ 2024-05-22T10:29:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/altrubio-secures-225m-funds/ 2024-05-22T08:05:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-partnership-drug-development/ 2024-05-22T07:56:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-collaborates-with-aktis-to-strengthen-radiopharma-portfolio/ 2024-05-21T16:24:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roches-pi3k-inhibitor-secures-breakthrough-status-in-breast-cancer/ 2024-05-21T16:13:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/larimar-resumes-nomlabofusp-programme-after-fda-lifts-partial-hold/ 2024-05-21T16:22:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pheon-cashes-in-on-adc-trend-and-raises-120m-in-series-b/ 2024-05-21T15:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/explainer-us-election-2024-bidens-healthcare-outlook/ 2024-05-21T14:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/glenmark-beigene-oncology-medicines-india/ 2024-05-21T10:23:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amplifybio-xcell-cell-therapy/ 2024-12-18T10:31:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approval-eylea-biosimilars/ 2024-05-22T08:45:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-adc-production-facility/ 2024-05-21T07:59:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/sweden-m-a-activity-pharmaceutical-industry/ 2024-09-10T02:25:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-personalization-pharmaceutical-industry/ 2024-05-21T02:28:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/privateequity-activity-future-of-work-pharmaceutical-industry/ 2024-05-21T02:28:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-individualism-expression-pharmaceutical-industry/ 2024-05-21T02:28:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/final-report-says-uk-infected-blood-scandal-should-have-been-avoided/ 2024-05-20T16:27:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgen-and-astrazeneca-ponder-label-expansion-for-tezspire-in-copd/ 2024-05-20T15:07:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-clinical-trials-industry-tackles-recent-changes-in-the-sector/ 2024-06-05T12:35:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cervical-cancer-elimination-uk-is-within-sight-with-hpv-vaccine/ 2024-05-20T13:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-to-identify-and-remove-cns-assessment-errors-before-jeapordising-a-trial/ 2024-05-20T14:13:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-zai-lab-xacduro/ 2024-05-20T10:03:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-suspension-17-ohpc-medicines/ 2024-05-20T09:55:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/pharmaceutical-lyophilization/ 2025-11-07T10:34:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/cutting-losses-in-drug-manufacturing-a-new-era-in-fill-finish-technology/ 2025-07-03T10:08:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-patent-case-astrazeneca/ 2024-05-20T08:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/serum-institute-of-india-integrimedical/ 2024-05-20T08:06:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/furmonertinib-mesylate-shanghai-allist-pharmaceuticals-lung-adenocarcinoma-likelihood-of-approval/ 2024-06-19T16:10:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olverembatinib-ascentage-pharma-group-international-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:01:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elixcyte-unicocell-biomed-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-05-20T05:46:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2025-01-21T17:01:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-neuroblastoma-likelihood-of-approval/ 2025-01-21T17:01:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-osteosarcoma-likelihood-of-approval/ 2025-01-21T17:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dipraglurant-addex-therapeutics-blepharospasm-likelihood-of-approval/ 2024-09-09T05:59:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-038-prolynx-recurrent-medulloblastoma-likelihood-of-approval/ 2025-01-21T16:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-038-prolynx-ependymoma-likelihood-of-approval/ 2025-01-21T16:59:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T16:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wp-1302-worg-pharmaceuticals-hangzhou-graves-diseases-likelihood-of-approval/ 2024-09-09T05:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onabotulinumtoxin-a-abbvie-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-21T16:57:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-primary-systemic-amyloidosis-likelihood-of-approval/ 2025-01-21T16:56:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annamycin-moleculin-biotech-soft-tissue-sarcoma-likelihood-of-approval/ 2024-09-09T05:57:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/collagenase-clostridium-histolyticum-endo-international-hand-foot-and-mouth-disease-likelihood-of-approval/ 2025-01-21T16:56:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-metapneumovirus-parainfluenza-virus-respiratory-syncytial-virus-vaccine-sanofi-human-metapneumovirus-infections-likelihood-of-approval/ 2024-07-05T18:26:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-metapneumovirus-parainfluenza-virus-respiratory-syncytial-virus-vaccine-sanofi-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-07-05T18:26:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/4th-generation-pcv-program-pfizer-streptococcal-pneumonia-likelihood-of-approval/ 2024-09-09T05:56:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3885125-eli-lilly-and-co-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-07-05T18:25:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zl-1310-zai-lab-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T16:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksp-1007-sumitomo-pharma-ventilator-associated-pneumonia-vap-likelihood-of-approval/ 2025-01-21T16:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gc-101-shanghai-juncell-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T05:55:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efzimfotase-alfa-alexion-pharmaceuticals-hypophosphatasia-likelihood-of-approval/ 2025-01-21T16:53:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-celltrion-bone-disorders-likelihood-of-approval/ 2025-01-21T16:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lutetium-miltuximab-glytherix-metastatic-prostate-cancer-likelihood-of-approval/ 2024-05-20T05:33:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lutetium-miltuximab-glytherix-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-05-20T05:33:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-97540-bristol-myers-squibb-relapsing-multiple-sclerosis-rms-likelihood-of-approval/ 2024-07-05T18:20:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-97540-bristol-myers-squibb-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-07-05T18:20:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-97540-bristol-myers-squibb-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2024-07-05T18:20:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-breast-cancer-likelihood-of-approval/ 2025-01-21T16:53:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocadusertib-eli-lilly-and-co-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-21T16:53:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avt-001-avotres-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-09-09T05:53:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T16:51:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T16:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:51:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/recaticimab-jiangsu-hengrui-medicine-heterozygous-familial-hypercholesterolemia-hefh-likelihood-of-approval/ 2025-01-21T16:51:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirpiglenastat-dracen-pharmaceuticals-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-05-20T05:26:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-obsessive-compulsive-disorder-likelihood-of-approval/ 2025-01-21T16:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T16:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rucaparib-camsylate-pharmaand-cervical-cancer-likelihood-of-approval/ 2024-05-20T03:32:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rucaparib-camsylate-pharmaand-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-05-20T02:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rucaparib-camsylate-pharmaand-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-05-20T02:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rucaparib-camsylate-pharmaand-renal-cell-carcinoma-likelihood-of-approval/ 2024-05-20T02:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rucaparib-camsylate-pharmaand-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-05-20T02:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/skinte-regenetp-diabetic-foot-ulcers-likelihood-of-approval/ 2024-05-20T01:29:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/direct-to-consumer-channels-change-patient-healthcare-system-relationship/ 2024-05-17T18:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-expands-dermatology-portfolio-with-850m-proteologix-acquisition/ 2024-05-17T18:18:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanders-issues-warning-to-novo-nordisk-amid-glp-1-drug-price-investigation/ 2024-05-17T14:36:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/erasca-trims-workforce-and-pipeline-to-focus-on-kras-and-molecular-glues/ 2024-05-17T13:45:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/galapagos-car-t-therapy-production/ 2024-12-18T10:39:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-breakthrough-nuvalent-nvl-655/ 2024-05-17T10:19:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cindome-secures-40m-gastroparesis/ 2024-05-17T08:53:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moxifloxacin-laboratorios-sophia-bacterial-conjunctivitis-likelihood-of-approval/ 2024-05-17T10:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/il13r-alpha-2-car-t-tcr-cure-biopharma-technology-glioma-likelihood-of-approval/ 2024-05-17T08:16:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mai-001-nanjing-minova-pharmaceutical-technology-depression-likelihood-of-approval/ 2024-05-17T08:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-cannamore-biotechs-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T02:20:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-for-parkinson-s-disease-innervate-therapeutics-parkinson-s-disease-likelihood-of-approval/ 2024-05-17T08:15:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-7563-phait-lung-cancer-likelihood-of-approval/ 2024-05-17T08:15:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-6452-phait-lung-cancer-likelihood-of-approval/ 2024-05-17T08:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-mycomedica-life-sciences-pbc-premenstrual-dysphoric-disorder-pmdd-likelihood-of-approval/ 2024-05-17T08:14:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-mycomedica-life-sciences-pbc-opium-opioid-addiction-likelihood-of-approval/ 2024-05-17T08:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-mycomedica-life-sciences-pbc-obsessive-compulsive-disorder-likelihood-of-approval/ 2024-05-17T08:13:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alm-401-almirall-autoimmune-disorders-likelihood-of-approval/ 2025-01-22T02:20:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-753-gilead-sciences-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-05-17T08:12:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-969-abbvie-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T02:20:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-911-biomed-industries-stroke-likelihood-of-approval/ 2024-05-17T08:12:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-87704916-johnson-johnson-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-17T08:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-87704916-johnson-johnson-solid-tumor-likelihood-of-approval/ 2024-05-17T08:11:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-118-vertex-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2024-05-17T08:11:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgen-imdelltra-fda-approval/ 2024-05-17T08:16:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpcn-2203-lipocine-essential-tremor-likelihood-of-approval/ 2024-05-17T08:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viroksavir-traws-pharma-pandemic-influenza-likelihood-of-approval/ 2025-01-22T02:20:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viroksavir-traws-pharma-seasonal-influenza-likelihood-of-approval/ 2025-01-22T02:20:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viroksavir-traws-pharma-haemophilus-influenzae-type-b-infections-likelihood-of-approval/ 2025-01-22T02:20:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viroksavir-traws-pharma-haemophilus-influenzae-type-a-infections-likelihood-of-approval/ 2025-01-22T02:20:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T18:49:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-07-05T18:49:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-07-05T18:49:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T18:49:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-07-05T18:49:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-solid-tumor-likelihood-of-approval/ 2024-07-05T18:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkt-3447-nikang-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:49:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-1965-alyssum-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T02:20:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-1965-alyssum-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-22T02:20:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-haleon-stake-divestiture/ 2024-05-17T08:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gridegalutamide-bristol-myers-squibb-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-05-17T08:06:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-01194-ipsen-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-05-17T08:05:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-01194-ipsen-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-05-17T08:05:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-01194-ipsen-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-05-17T08:05:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-01194-ipsen-solid-tumor-likelihood-of-approval/ 2024-05-17T08:04:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-01194-ipsen-metastatic-melanoma-likelihood-of-approval/ 2024-05-17T08:04:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/da-5219-dong-a-st-gastritis-likelihood-of-approval/ 2024-05-17T08:04:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-3470-astrazeneca-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:17:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-6491-novo-nordisk-dyslipidemia-likelihood-of-approval/ 2024-05-17T08:02:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-1167-merck-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2024-05-17T08:02:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iam-1363-iambic-therapeutics-solid-tumor-likelihood-of-approval/ 2024-07-05T18:49:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyt-101-cyteph-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-05-17T08:01:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyt-101-cyteph-astrocytoma-likelihood-of-approval/ 2024-05-17T08:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:20:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-22T02:20:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:19:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:19:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T02:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:19:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:19:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-901-edigene-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mynflu-001-mynvax-seasonal-influenza-likelihood-of-approval/ 2024-05-17T07:59:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-hyaluronidase-human-recombinant-argenx-graves-ophthalmopathy-likelihood-of-approval/ 2025-01-22T02:19:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dm-919-d2m-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-05-17T07:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rv-1770-rnaimmune-inc-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2025-01-22T02:19:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-2100-arsenal-biosciences-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-05-17T07:57:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-129-innovent-biologics-solid-tumor-likelihood-of-approval/ 2025-01-22T02:19:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-1300-biohaven-rheumatoid-arthritis-likelihood-of-approval/ 2024-05-17T07:56:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meningococcal-polysaccharide-serotypes-a-c-w-135-y-vaccine-cansino-biologics-neisseria-meningitidis-infections-likelihood-of-approval/ 2025-01-22T02:19:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xkh-002-suzhou-xinkanghe-biomedical-technology-solid-tumor-likelihood-of-approval/ 2024-05-17T07:56:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbi-825-boundless-bio-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-05-17T07:55:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbi-825-boundless-bio-solid-tumor-likelihood-of-approval/ 2024-05-17T07:55:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nrct-101sr-neurocentria-attention-deficit-hyperactivity-disorder-adhd-likelihood-of-approval/ 2024-05-17T07:55:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-3018250-bayer-acute-ischemic-stroke-likelihood-of-approval/ 2025-01-22T02:19:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-3018250-bayer-pulmonary-embolism-likelihood-of-approval/ 2025-01-22T02:19:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lyophilized-microbiota-gut-brain-axis-therapeutics-abdominal-pain-likelihood-of-approval/ 2025-01-22T02:19:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lyophilized-microbiota-gut-brain-axis-therapeutics-mutational-disorders-likelihood-of-approval/ 2025-01-22T02:19:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lyophilized-microbiota-gut-brain-axis-therapeutics-constipation-likelihood-of-approval/ 2025-01-22T02:19:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/men-2312-stemline-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:19:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/men-2312-stemline-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-22T02:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-808-apogee-therapeutics-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-22T02:19:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-808-apogee-therapeutics-inflammation-likelihood-of-approval/ 2025-01-22T02:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-808-apogee-therapeutics-asthma-likelihood-of-approval/ 2025-01-22T02:19:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nest-1-nested-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-17T07:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nest-1-nested-therapeutics-glioma-likelihood-of-approval/ 2024-05-17T07:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nest-1-nested-therapeutics-melanoma-likelihood-of-approval/ 2024-05-17T07:50:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0305-astrazeneca-refractory-multiple-myeloma-likelihood-of-approval/ 2024-07-05T18:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0305-astrazeneca-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-07-05T18:49:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sys-6002-corbus-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2025-01-22T02:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-2051-cytomx-therapeutics-epithelial-tumor-likelihood-of-approval/ 2025-01-22T02:18:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-2051-cytomx-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-22T02:18:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-2051-cytomx-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-22T02:18:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-102-forte-biosciences-alopecia-areata-likelihood-of-approval/ 2025-01-22T02:18:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-102-forte-biosciences-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-22T02:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-102-forte-biosciences-vitiligo-likelihood-of-approval/ 2025-01-22T02:18:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thyroid-abbvie-hypothyroidism-likelihood-of-approval/ 2024-06-19T16:29:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eloralintide-eli-lilly-and-co-obesity-likelihood-of-approval/ 2024-06-19T16:29:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aceclidine-brimonidine-lenz-therapeutics-presbyopia-likelihood-of-approval/ 2025-01-22T02:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aceclidine-lenz-therapeutics-presbyopia-likelihood-of-approval/ 2025-01-22T02:18:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-05-17T07:37:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-05-17T07:37:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-05-17T07:37:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-17T07:37:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-solid-tumor-likelihood-of-approval/ 2024-05-17T07:36:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-melanoma-likelihood-of-approval/ 2024-05-17T07:36:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/212pb-dotam-grpr1-orano-med-cervical-cancer-likelihood-of-approval/ 2024-05-17T07:36:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-22T02:18:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:18:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-22T02:18:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-peritoneal-cancer-likelihood-of-approval/ 2025-01-22T02:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-22T02:18:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-22T02:18:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-1511-nuvation-bio-ovarian-cancer-likelihood-of-approval/ 2025-01-22T02:18:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnc-04870111-novo-nordisk-obesity-likelihood-of-approval/ 2025-01-22T02:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taa06-ucar-gammadeltat-persongen-biotherapeutics-suzhou-solid-tumor-likelihood-of-approval/ 2025-01-22T02:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-edison-oncology-holding-rhabdomyosarcoma-likelihood-of-approval/ 2024-05-17T07:33:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-edison-oncology-holding-neuroblastoma-likelihood-of-approval/ 2024-05-17T07:33:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-edison-oncology-holding-medulloblastoma-likelihood-of-approval/ 2024-05-17T07:32:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-edison-oncology-holding-ewing-sarcoma-likelihood-of-approval/ 2024-05-17T07:32:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-edison-oncology-holding-hepatic-liver-tumor-likelihood-of-approval/ 2024-05-17T07:32:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dlq-01-dermaliq-therapeutics-androgenic-alopecia-likelihood-of-approval/ 2024-05-17T07:32:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-443809-sanofi-paroxysmal-nocturnal-hemoglobinuria-likelihood-of-approval/ 2025-01-22T02:17:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-07-05T18:48:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-07-05T18:48:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:48:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T18:48:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-07-05T18:48:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T18:48:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-07-05T18:48:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:48:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-07-05T18:48:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-endometrial-cancer-likelihood-of-approval/ 2024-07-05T18:48:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-solid-tumor-likelihood-of-approval/ 2024-07-05T18:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-sarcomas-likelihood-of-approval/ 2024-07-05T18:48:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T18:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-melanoma-likelihood-of-approval/ 2024-07-05T18:48:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:48:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-07-05T18:48:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-metastatic-breast-cancer-likelihood-of-approval/ 2024-07-05T18:48:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-bladder-cancer-likelihood-of-approval/ 2024-07-05T18:48:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:48:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgc-026-macrogenics-cervical-cancer-likelihood-of-approval/ 2024-07-05T18:47:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qn-302-qualigen-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-22T02:17:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-60106-jd-bioscience-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-22T02:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thdbh-150-tonghua-dongbao-pharmaceutical-gouty-arthritis-gout-likelihood-of-approval/ 2024-05-17T07:23:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thdbh-150-tonghua-dongbao-pharmaceutical-hyperuricemia-likelihood-of-approval/ 2024-05-17T07:23:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alto-202-alto-neuroscience-major-depressive-disorder-likelihood-of-approval/ 2024-05-17T07:22:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibuprofen-oxycodone-eurofarma-laboratorios-pain-likelihood-of-approval/ 2025-01-22T02:17:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbo-8520-bridgebio-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:17:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gpc-201-gpcr-therapeutics-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-05-17T07:22:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scdaric-33-regeneron-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:17:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scdaric-33-regeneron-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:17:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-chronic-cutaneous-lupus-erythematosus-ccle-discoid-lupus-erythematosus-dle-likelihood-of-approval/ 2025-01-22T02:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-22T02:17:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-vaccine-pfizer-influenzavirus-b-infections-likelihood-of-approval/ 2024-05-17T07:20:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-vaccine-pfizer-influenzavirus-a-infections-likelihood-of-approval/ 2024-05-17T07:20:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01488-transthera-sciences-nanjing-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-19T16:29:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1365-moderna-human-metapneumovirus-infections-likelihood-of-approval/ 2024-07-05T18:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3541860-eli-lilly-and-co-relapsing-multiple-sclerosis-rms-likelihood-of-approval/ 2025-01-22T02:17:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luna-18-chugai-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-22T02:17:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-modified-cell-therapy-to-target-cd33-for-relapsed-and-refractory-acute-myeloid-leukemia-sichuan-kelun-biotech-biopharmaceutical-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-05-17T07:18:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-modified-cell-therapy-to-target-cd33-for-relapsed-and-refractory-acute-myeloid-leukemia-sichuan-kelun-biotech-biopharmaceutical-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-05-17T07:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-193-azora-therapeutics-hidradenitis-suppurativa-likelihood-of-approval/ 2024-05-17T07:17:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tn-401-tenaya-therapeutics-cardiomyopathy-likelihood-of-approval/ 2025-01-22T02:17:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-quavonlimab-merck-solid-tumor-likelihood-of-approval/ 2025-01-22T02:17:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-quavonlimab-merck-metastatic-melanoma-likelihood-of-approval/ 2025-01-22T02:17:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-quavonlimab-merck-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-07d1-systimmune-gynecological-cancer-likelihood-of-approval/ 2025-01-22T02:17:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/da-1726-neurobo-pharmaceuticals-obesity-likelihood-of-approval/ 2025-01-22T02:17:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eye-103-eyebiotech-diabetic-macular-edema-likelihood-of-approval/ 2025-01-22T02:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-001-suzhou-immunofoco-biotechnology-liver-cancer-likelihood-of-approval/ 2025-01-22T02:16:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgt-003-solid-biosciences-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-05-17T07:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ranibizumab-biosimilar-shanghai-biomabs-pharmaceuticals-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-05T18:47:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tx-000045-tectonic-therapeutic-inc-pulmonary-hypertension-likelihood-of-approval/ 2025-01-22T02:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0034-huabo-biopharm-shanghai-pyoderma-gangrenosum-likelihood-of-approval/ 2025-01-22T02:16:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0034-huabo-biopharm-shanghai-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-22T02:16:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0034-huabo-biopharm-shanghai-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-22T02:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tavo-101-tavotek-biotherapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-06-19T16:28:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abi-4334-assembly-biosciences-hepatitis-b-likelihood-of-approval/ 2024-05-17T07:12:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ecc-4703-eccogene-shanghai-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-22T02:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-3232-ventyx-biosciences-multiple-sclerosis-likelihood-of-approval/ 2025-01-22T02:16:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyb-004-cybin-generalized-anxiety-disorder-gad-likelihood-of-approval/ 2024-09-09T06:16:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cs-1103-clear-scientific-substance-drug-abuse-likelihood-of-approval/ 2024-05-17T07:07:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ath-1020-athira-pharma-schizophrenia-likelihood-of-approval/ 2024-05-17T07:07:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ath-1020-athira-pharma-depression-likelihood-of-approval/ 2024-05-17T07:07:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ath-1020-athira-pharma-anxiety-disorders-likelihood-of-approval/ 2024-05-17T07:06:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ath-1020-athira-pharma-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-05-17T07:06:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jskn-003-alphamab-oncology-esophageal-cancer-likelihood-of-approval/ 2025-01-22T02:16:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jskn-003-alphamab-oncology-gastric-cancer-likelihood-of-approval/ 2025-01-22T02:16:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jskn-003-alphamab-oncology-head-and-neck-cancer-likelihood-of-approval/ 2025-01-22T02:16:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jskn-003-alphamab-oncology-lung-cancer-likelihood-of-approval/ 2025-01-22T02:16:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jskn-003-alphamab-oncology-breast-cancer-likelihood-of-approval/ 2025-01-22T02:16:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-291-sana-biotechnology-microscopic-polyangiitis-mpa-likelihood-of-approval/ 2025-01-22T02:16:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-291-sana-biotechnology-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-likelihood-of-approval/ 2025-01-22T02:16:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-291-sana-biotechnology-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2025-01-22T02:16:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-291-sana-biotechnology-lupus-nephritis-likelihood-of-approval/ 2025-01-22T02:16:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-291-sana-biotechnology-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-22T02:16:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suzetrigine-vertex-pharmaceuticals-diabetic-peripheral-neuropathy-likelihood-of-approval/ 2025-01-22T02:16:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suzetrigine-vertex-pharmaceuticals-radiculopathy-likelihood-of-approval/ 2025-01-22T02:16:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suzetrigine-vertex-pharmaceuticals-post-operative-pain-likelihood-of-approval/ 2025-01-22T02:15:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:16:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-09-09T06:16:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:16:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:15:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:15:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-22T02:15:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:15:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-22T02:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T02:15:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmcd19-il18-kite-pharma-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-22T02:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-09-09T06:15:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T06:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:15:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T06:15:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-endometrial-cancer-likelihood-of-approval/ 2024-09-09T06:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-solid-tumor-likelihood-of-approval/ 2024-09-09T06:15:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-head-and-neck-cancer-likelihood-of-approval/ 2024-09-09T06:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-colorectal-cancer-likelihood-of-approval/ 2024-09-09T06:15:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-10-portage-biotech-ovarian-cancer-likelihood-of-approval/ 2024-09-09T06:15:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-1-104-immuneering-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-22T02:15:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-1-104-immuneering-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-22T02:15:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxe-0048149-nxera-pharma-schizophrenia-likelihood-of-approval/ 2025-01-22T02:15:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrt-106-guangzhou-virotech-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-22T02:15:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vq-101-vanqua-bio-parkinson-s-disease-likelihood-of-approval/ 2025-01-22T02:15:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemlapodect-noema-pharma-tourette-syndrome-likelihood-of-approval/ 2024-05-17T06:47:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemlapodect-noema-pharma-stammering-stuttering-likelihood-of-approval/ 2024-05-17T06:46:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saruparib-astrazeneca-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-07-05T18:46:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3s-001-d3-bio-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-22T02:15:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3s-001-d3-bio-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:15:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3s-001-d3-bio-solid-tumor-likelihood-of-approval/ 2025-01-22T02:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3s-001-d3-bio-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-22T02:15:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kan-002-kanvas-biosciences-inflammatory-bowel-disease-likelihood-of-approval/ 2024-05-17T06:41:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-236-vincerx-pharma-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2025-01-22T02:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-236-vincerx-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:15:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-236-vincerx-pharma-solid-tumor-likelihood-of-approval/ 2025-01-22T02:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-236-vincerx-pharma-gastric-cancer-likelihood-of-approval/ 2025-01-22T02:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vip-236-vincerx-pharma-colorectal-cancer-likelihood-of-approval/ 2025-01-22T02:14:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vvn-001-viva-vision-biotech-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-22T02:14:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xw-10508-xwpharma-major-depressive-disorder-likelihood-of-approval/ 2024-05-17T06:38:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atirmociclib-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T02:14:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atirmociclib-pfizer-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T17:31:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rs-1805-reistone-biopharma-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T17:31:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcd-180-biocad-ankylosing-spondylitis-bekhterev-s-disease-likelihood-of-approval/ 2024-05-17T06:37:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncarlytics-imugene-melanoma-likelihood-of-approval/ 2025-01-21T17:31:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncarlytics-imugene-breast-cancer-likelihood-of-approval/ 2025-01-21T17:31:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spx-303-sparx-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T17:31:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexanolone-seaport-therapeutics-major-depressive-disorder-likelihood-of-approval/ 2025-01-21T17:31:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peel-224-peel-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T17:31:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lmy-920-luminary-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-21T17:30:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lmy-920-luminary-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-21T17:30:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gh-21-huya-bioscience-international-solid-tumor-likelihood-of-approval/ 2025-01-21T17:30:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-19123-lg-chem-type-2-diabetes-likelihood-of-approval/ 2024-05-17T06:32:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amidosulfonate-silver-lactone-b-jiangsu-carephar-pharmaceutical-acute-ischemic-stroke-likelihood-of-approval/ 2024-05-17T06:32:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrg-50635-verge-analytics-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-05-17T06:32:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avi-4015-enzychem-lifesciences-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-05-17T06:32:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-5668-regeneron-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:30:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plb-1004-avistone-biotechnology-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:30:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gl-0034-sun-pharmaceutical-industries-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2025-01-21T17:30:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065890-neurocrine-biosciences-psychiatric-disorders-likelihood-of-approval/ 2024-05-17T06:30:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-21T17:30:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T17:30:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:30:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:30:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:30:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:30:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-esophageal-cancer-likelihood-of-approval/ 2025-01-21T17:30:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:30:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:30:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T17:30:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:29:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T17:29:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:29:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T17:29:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-melanoma-likelihood-of-approval/ 2025-01-21T17:29:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-21T17:29:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:29:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-0796-nodthera-atherosclerosis-likelihood-of-approval/ 2025-01-21T17:29:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:29:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T17:29:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:29:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T17:29:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-albumin-bound-cspc-pharmaceutical-group-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:29:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vxc-522-vertex-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2024-05-17T06:19:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ax-158-artax-biopharma-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-09-09T06:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ax-158-artax-biopharma-autoimmune-disorders-likelihood-of-approval/ 2024-09-09T06:14:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-21T17:29:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:29:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-21T17:29:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:28:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:28:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/decoy-20-indaptus-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T17:28:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oxytocin-ot4b-prader-willi-syndrome-pws-likelihood-of-approval/ 2025-01-21T17:28:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/testosterone-tridecanoate-lipocine-decompensated-cirrhosis-likelihood-of-approval/ 2024-05-17T06:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T17:28:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:28:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:28:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-t-cell-lymphomas-likelihood-of-approval/ 2025-01-21T17:28:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-solid-tumor-likelihood-of-approval/ 2025-01-21T17:28:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T17:28:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-melanoma-likelihood-of-approval/ 2025-01-21T17:28:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-prostate-cancer-likelihood-of-approval/ 2025-01-21T17:28:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xtx-301-gilead-sciences-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:28:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ninerafaxstat-imbria-pharmaceuticals-hypertrophic-cardiomyopathy-likelihood-of-approval/ 2024-07-05T18:44:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-707-sirnaomics-liver-fibrosis-likelihood-of-approval/ 2025-01-21T17:28:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovilnesib-volastra-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-05-17T06:12:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-1427-gilead-sciences-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T17:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sbt-777101-sonoma-biotherapeutics-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-21T17:27:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gnospv-02-geneos-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T17:27:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-6-415-immuneering-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:27:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-6-415-immuneering-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:27:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-6-415-immuneering-solid-tumor-likelihood-of-approval/ 2025-01-21T17:27:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-6-415-immuneering-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T17:27:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-6-415-immuneering-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:27:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-6-415-immuneering-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:27:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gbm-2-cellworks-group-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-05-17T06:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qel-001-quell-therapeutics-liver-transplant-rejection-likelihood-of-approval/ 2024-06-19T16:25:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-3011-immvira-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:27:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imt-009-immunitas-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T17:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maat-033-maat-pharma-axial-spondyloarthritis-likelihood-of-approval/ 2025-01-21T17:27:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-solid-tumor-likelihood-of-approval/ 2025-01-21T17:27:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sp-0218-sanofi-yellow-fever-likelihood-of-approval/ 2024-05-17T06:04:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sq-3370-shasqi-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:27:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alg-009-aligos-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-07-05T18:44:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpg-1860-hepagene-therapeutics-shanghai-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2025-01-21T17:27:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/procizumab-4teen4-pharmaceuticals-acute-heart-failure-likelihood-of-approval/ 2024-05-17T06:03:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/procizumab-4teen4-pharmaceuticals-cardiogenic-shock-likelihood-of-approval/ 2024-05-17T06:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-salivary-gland-cancer-likelihood-of-approval/ 2025-01-21T17:27:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-05-17T06:01:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-05-17T06:01:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-05-17T06:01:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-oropharyngeal-cancer-likelihood-of-approval/ 2024-05-17T06:00:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-laryngeal-cancer-likelihood-of-approval/ 2024-05-17T06:00:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-hypopharyngeal-cancer-likelihood-of-approval/ 2024-05-17T06:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-17T05:59:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-05-17T05:59:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-8371-compass-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-05-17T05:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebx-102-enterobiotix-irritable-bowel-syndrome-likelihood-of-approval/ 2024-06-19T16:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:26:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-bladder-cancer-likelihood-of-approval/ 2025-01-21T17:26:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-101-encoded-therapeutics-dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-likelihood-of-approval/ 2024-05-17T05:55:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-solid-tumor-likelihood-of-approval/ 2025-01-21T17:26:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doc-1021-diakonos-oncology-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-09-09T06:13:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doc-1021-diakonos-oncology-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-09-09T06:13:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T17:26:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2025-01-21T17:26:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:26:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-malignant-pleural-mesothelioma-likelihood-of-approval/ 2025-01-21T17:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:26:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-solid-tumor-likelihood-of-approval/ 2025-01-21T17:26:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:26:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-95024-les-laboratoires-servier-cervical-cancer-likelihood-of-approval/ 2025-01-21T17:26:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ob-756-hangzhou-east-china-pharmaceutical-group-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-21T17:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-shanghai-henlius-biotech-post-menopausal-osteoporosis-likelihood-of-approval/ 2025-01-21T17:26:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremtelectogene-empogeditemcel-vor-biopharma-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T17:26:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-007-beigene-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:26:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-007-beigene-cervical-cancer-likelihood-of-approval/ 2025-01-21T17:26:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-161-biontech-seasonal-influenza-likelihood-of-approval/ 2024-05-17T05:50:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-161-biontech-influenzavirus-b-infections-likelihood-of-approval/ 2024-05-17T05:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-161-biontech-influenzavirus-a-infections-likelihood-of-approval/ 2024-05-17T05:49:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nusepin-hudson-therapeutics-pneumonia-likelihood-of-approval/ 2024-05-17T05:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ni-004-neurimmune-alzheimer-s-disease-likelihood-of-approval/ 2024-05-17T05:49:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alx-001-allyx-therapeutics-parkinson-s-disease-likelihood-of-approval/ 2025-01-21T17:25:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yl-13027-shanghai-yingli-pharmaceutical-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-21T17:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elritercept-keros-therapeutics-anemia-likelihood-of-approval/ 2024-09-09T06:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prgn-2012-precigen-recurrent-respiratory-papillomatosis-juvenile-laryngeal-papilloma-or-laryngeal-papilloma-likelihood-of-approval/ 2025-01-21T17:25:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbt-369-regeneron-pharmaceuticals-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:25:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbt-369-regeneron-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T17:25:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbt-369-regeneron-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:25:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selvigaltin-galecto-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:25:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zocaglusagene-nuzaparvovec-astellas-gene-therapies-pompe-disease-likelihood-of-approval/ 2024-05-17T05:44:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdtx-1535-black-diamond-therapeutics-high-grade-glioma-likelihood-of-approval/ 2024-06-19T16:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adapt-001-epicentrx-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T06:13:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-1011-sinomab-bioscience-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-05-17T05:42:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frespaciguat-merck-pulmonary-hypertension-likelihood-of-approval/ 2025-01-21T17:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tindupepimut-enterome-bioscience-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T17:25:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-6070-merck-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:25:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-6070-merck-prostate-cancer-likelihood-of-approval/ 2025-01-21T17:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/topotecan-hydrochloride-fujifilm-merkel-cell-carcinoma-likelihood-of-approval/ 2024-05-17T05:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/topotecan-hydrochloride-fujifilm-solid-tumor-likelihood-of-approval/ 2024-05-17T05:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T17:25:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:25:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syx-1042-eli-lilly-and-co-inflammation-likelihood-of-approval/ 2025-01-21T17:25:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syx-1042-eli-lilly-and-co-autoimmune-disorders-likelihood-of-approval/ 2025-01-21T17:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/progerinin-prg-s-tech-hutchinson-gilford-progeria-likelihood-of-approval/ 2024-06-19T16:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-002-immuneoncia-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T17:25:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-002-immuneoncia-therapeutics-lymphoma-likelihood-of-approval/ 2025-01-21T17:25:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vutiglabridin-glaceum-parkinson-s-disease-likelihood-of-approval/ 2025-01-21T17:24:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:24:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-sarcomas-likelihood-of-approval/ 2025-01-21T17:24:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:24:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T17:24:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T17:24:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T17:24:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgn-1-guangzhou-huajin-pharmaceutical-technology-breast-cancer-likelihood-of-approval/ 2025-01-21T17:24:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exl-01-exeliom-biosciences-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2025-01-21T17:24:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxp-800-nuvectis-pharma-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-21T17:24:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-relatlimab-bristol-myers-squibb-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:24:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinengotinib-transthera-sciences-nanjing-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T17:24:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-6ng-autolus-therapeutics-glioma-likelihood-of-approval/ 2024-09-09T06:11:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalutrafusp-alfa-agenus-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:24:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-esophageal-cancer-likelihood-of-approval/ 2025-01-21T17:24:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-cspc-pharmaceutical-group-ewing-sarcoma-likelihood-of-approval/ 2025-01-21T17:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/redasemtide-trifluoroacetate-shionogi-dilated-cardiomyopathy-likelihood-of-approval/ 2025-01-21T17:24:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-dragonboat-biopharmaceutical-shanghai-penile-cancer-likelihood-of-approval/ 2025-01-21T17:23:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/szn-043-surrozen-alcoholic-hepatitis-likelihood-of-approval/ 2025-01-21T17:23:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tjc-0265-taiwanj-pharmaceuticals-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-05-17T05:27:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-210c-axoltis-pharma-alzheimer-s-disease-likelihood-of-approval/ 2025-01-21T17:23:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yg-1699-youngene-therapeutics-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2024-05-17T05:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:23:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mevrometostat-pfizer-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:23:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mevrometostat-pfizer-prostate-cancer-likelihood-of-approval/ 2025-01-21T17:23:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/basroparib-st-pharm-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T17:23:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/basroparib-st-pharm-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T17:23:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/basroparib-st-pharm-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:23:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/basroparib-st-pharm-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligufalimab-akeso-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T17:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ninsipapogene-sibarnarepvec-hookipa-pharma-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:23:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-901-biomed-industries-alzheimer-s-disease-likelihood-of-approval/ 2024-05-17T05:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ubamatamab-regeneron-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-08-cartesian-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T17:23:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giga-564-gigagen-solid-tumor-likelihood-of-approval/ 2025-01-21T17:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:22:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T17:22:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:22:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T17:22:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:22:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-21T17:22:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-penile-cancer-likelihood-of-approval/ 2025-01-21T17:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-anal-cancer-likelihood-of-approval/ 2025-01-21T17:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-sarcomas-likelihood-of-approval/ 2025-01-21T17:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T17:22:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-bladder-cancer-likelihood-of-approval/ 2025-01-21T17:22:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-melanoma-likelihood-of-approval/ 2025-01-21T17:22:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:22:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dn-1508052-shanghai-de-novo-pharmatech-prostate-cancer-likelihood-of-approval/ 2025-01-21T17:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abp-671-jiangsu-atom-bioscience-and-pharmaceutical-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-09-09T06:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inz-701-inozyme-pharma-pseudoxanthoma-elasticum-pxe-or-gronblad-strandberg-syndrome-likelihood-of-approval/ 2025-01-21T17:22:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jwtcr-001-medigene-solid-tumor-likelihood-of-approval/ 2024-05-17T04:17:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ssgj-609a-sunshine-guojian-pharmaceutical-shanghai-solid-tumor-likelihood-of-approval/ 2024-06-19T16:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selenium-sulfide-azura-ophthalmics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-21T17:21:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-vipivotide-tetraxetan-advanced-accelerator-applications-metastatic-prostate-cancer-likelihood-of-approval/ 2025-01-21T17:21:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zasocitinib-takeda-pharmaceutical-generalized-pustular-psoriasis-gpp-likelihood-of-approval/ 2025-01-21T17:21:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zasocitinib-takeda-pharmaceutical-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-21T17:21:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vamifeport-hydrochloride-vifor-pharma-management-sickle-cell-disease-likelihood-of-approval/ 2024-05-17T04:15:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hhcyh-33-shanghai-haihe-biopharma-endometrial-cancer-likelihood-of-approval/ 2024-06-19T16:23:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hhcyh-33-shanghai-haihe-biopharma-prostate-cancer-likelihood-of-approval/ 2024-06-19T16:23:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hhcyh-33-shanghai-haihe-biopharma-ovarian-cancer-likelihood-of-approval/ 2024-06-19T16:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cin-110-cinfina-pharma-obesity-likelihood-of-approval/ 2025-01-21T17:21:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orelabrutinib-innocare-pharma-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:21:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quavonlimab-merck-solid-tumor-likelihood-of-approval/ 2024-06-19T16:23:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quavonlimab-merck-metastatic-melanoma-likelihood-of-approval/ 2024-06-19T16:23:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quavonlimab-merck-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T16:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sp-0125-sanofi-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2025-01-21T17:21:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-solid-tumor-likelihood-of-approval/ 2025-01-21T17:21:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-21T17:21:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T17:21:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:21:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-21T17:21:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T17:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:21:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:21:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T17:20:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ov-329-ovid-therapeutics-seizures-likelihood-of-approval/ 2025-01-21T17:20:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arv-766-novartis-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T17:20:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-71-cstone-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T06:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-71-cstone-pharmaceuticals-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-71-cstone-pharmaceuticals-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-71-cstone-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-09-09T06:09:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-71-cstone-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcb-71-cstone-pharmaceuticals-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mozafancogene-autotemcel-rocket-pharmaceuticals-fanconi-anemia-likelihood-of-approval/ 2024-05-17T04:00:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T17:20:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:20:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T17:20:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tcp-25-in2cure-wounds-likelihood-of-approval/ 2025-01-21T17:20:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/601a-anti-vegf-ab-sunshine-guojian-pharmaceutical-shanghai-branch-retinal-vein-occlusion-likelihood-of-approval/ 2025-01-21T17:20:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaccine-for-celiac-disease-vactech-celiac-disease-likelihood-of-approval/ 2024-05-17T03:55:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/601a-anti-vegf-ab-sunshine-guojian-pharmaceutical-shanghai-diabetic-macular-edema-likelihood-of-approval/ 2025-01-21T17:20:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/601a-anti-vegf-ab-sunshine-guojian-pharmaceutical-shanghai-age-related-macular-degeneration-likelihood-of-approval/ 2025-01-21T17:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-07-05T18:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifaximin-ssd-bausch-health-hepatic-encephalopathy-likelihood-of-approval/ 2024-05-17T03:54:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-07-05T18:39:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-07-05T18:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-07-05T18:39:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-sezary-syndrome-likelihood-of-approval/ 2024-07-05T18:39:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nm-5072-novelmed-therapeutics-paroxysmal-nocturnal-hemoglobinuria-likelihood-of-approval/ 2025-01-21T17:20:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-122-icell-gene-therapeutics-t-cell-leukemia-likelihood-of-approval/ 2024-07-05T18:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tifcemalimab-shanghai-junshi-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-21T17:19:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-moderna-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esketamine-hydrochloride-celon-pharma-major-depressive-disorder-likelihood-of-approval/ 2024-05-17T03:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nesuparib-onconic-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/btxa-51-edgewood-oncology-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abiprubart-kiniksa-pharmaceuticals-sicca-syndrome-sjogren-likelihood-of-approval/ 2024-09-09T06:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/otl-201-orchard-therapeutics-mucopolysaccharidosis-iii-mps-iii-sanfilippo-syndrome-likelihood-of-approval/ 2024-05-17T03:47:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/btxa-51-edgewood-oncology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:19:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-09-09T06:09:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-09-09T06:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-09-09T06:09:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-non-proliferative-diabetic-retinopathy-npdr-likelihood-of-approval/ 2025-01-21T17:19:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-21T17:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-retinal-vein-occlusion-likelihood-of-approval/ 2025-01-21T17:19:29+00:00 daily 0.2